GlassScriptPhysician profile
Jonathan D Briggs
NPI 1053380220
$745.11
in general payments reported to CMS, 2019-2025
13 companies · $296 in 2025
The $296 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $115 · 2022: $53.96 · 2023: $128 · 2024: $152 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $576.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $323.21 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $98.93 | 2024-2025 | Farxiga, Airsupra |
| Pfizer INC. | $63.50 | 2024-2025 | |
| Dexcom, INC. | $48.56 | 2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $44.84 | 2021 | |
| Abbvie INC. | $35.41 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $32.10 | 2025 | Voquezna |
| Lilly USA, LLC | $25.71 | 2021-2025 | Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $17.37 | 2025 | Shingrix, Arexvy |
| Arbor Pharmaceuticals, INC. | $15.15 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.73 | 2021 | |
| Eisai INC. | $13.39 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.21 | 2024 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Briggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.